Novel application of metformin combined with targeted drugs on anticancer treatment
Open Access
- 25 October 2018
- journal article
- review article
- Published by Wiley in Cancer Science
- Vol. 110 (1) , 23-30
Abstract
The success of targeted drug therapies for treating cancer patients has attracted broad attention both in the academic community and social society. However, rapidly developed acquired resistance is becoming a newly recognized major challenge to the continuing efficiency of these therapies. Metformin is a well‐known natural compound with low toxicity derived from the plant French lilac. Our previous work has highlighted research progress of the combination of clinically applied chemotherapies and metformin by different mechanisms. We have also launched a study to combine metformin with the small molecule targeted drug gefitinib to treat bladder cancer using intravesical administration. Thus, in this minireview, we summarize recent achievements combining metformin with various targeted therapies. This work directs the potential clinical future by selecting available cancer patients and providing precise medicine by the combination of metformin and targeted drugs to overcome resistance and enhance therapeutic efficacies.Keywords
Funding Information
- National Natural Science Foundation of China (81703008, 81874212)
This publication has 69 references indexed in Scilit:
- Repositioning metformin for cancer prevention and treatmentTrends in Endocrinology & Metabolism, 2013
- Metformin, a Diabetes Drug, Eliminates Tumor-Initiating Hepatocellular Carcinoma CellsPLOS ONE, 2013
- Sorafenib: activity and clinical application in patients with hepatocellular carcinomaExpert Opinion on Pharmacotherapy, 2011
- Phase II Study of Sorafenib in Combination With Docetaxel and Cisplatin in the Treatment of Metastatic or Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: ECOG 5203Journal of Clinical Oncology, 2010
- Understanding resistance to EGFR inhibitors—impact on future treatment strategiesNature Reviews Clinical Oncology, 2010
- The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cellsBreast Cancer Research and Treatment, 2010
- mTOR and cancer: insights into a complex relationshipNature Reviews Cancer, 2006
- Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancerNature Reviews Drug Discovery, 2004
- FDA Drug Approval Summary: Gefitinib (ZD1839) (Iressa®) TabletsThe Oncologist, 2003
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neuOncogeneScience, 1987